Biontech SE
BNTX99.710USD
+3.170+3.28%
收盤 11/25, 16:00（美東）報價延遲15分鐘
23.98B總市值
虧損本益比TTM
關於 Biontech SE 公司
BioNTech SE 是一家位於德國的臨牀階段生物技術公司。該公司專注於針對癌症和其他嚴重疾病的患者特異性免疫療法。該公司提供的技術包括基於 mRNA 的療法、細胞療法、小分子和抗體，這些技術可用於特定目的，甚至可以以協同方式相互結合。該公司還利用不同的科學方法和技術平臺開發了廣泛的產品線，包括個性化的基於 mRNA 的產品候選物、嵌合抗原受體 T 細胞、檢查點免疫調節劑、靶向癌症抗體和小分子。此外，該公司還爲其他治療領域提供診斷產品和藥物發現服務，包括傳染病、過敏和自身免疫性疾病。
Biontech SE簡介
公司代碼BNTX
公司名稱Biontech SE
上市日期Oct 10, 2019
CEOProf. Ugur Sahin, M.D.
員工數量6772
證券類型Depository Receipt
年結日Oct 10
公司地址An der Goldgrube 12
城市MAINZ
上市交易所NASDAQ Global Select Consolidated
國家Germany
郵編55131
電話4949613190840
網址https://www.biontech.com/
公司代碼BNTX
上市日期Oct 10, 2019
CEOProf. Ugur Sahin, M.D.
Biontech SE公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Mr. Ramon Zapata Gomez
Mr. Ramon Zapata Gomez
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Ms. Baroness Nicola Blackwood
Ms. Baroness Nicola Blackwood
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Ms. Annemarie Hanekamp
Ms. Annemarie Hanekamp
Member of the Management Board, Chief Commercial Officer
Member of the Management Board, Chief Commercial Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Mr. Ramon Zapata Gomez
Mr. Ramon Zapata Gomez
Chief Financial Officer
Chief Financial Officer
--
--
收入明細
單位: USD更新時間: 3月12日 週三
單位: USD更新時間: 3月12日 週三
FY2019
FY2018
FY2017
業務USD
名稱
營收
佔比
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
由於公司未披露，未能獲取相關數據
業務
地區
業務USD
名稱
營收
佔比
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
股東統計
更新時間: 11月15日 週六
更新時間: 11月15日 週六
持股股東
股東類型
持股股東
持股股東
佔比
AT Impf GmbH
42.36%
Medine GmbH
16.69%
Baillie Gifford & Co.
3.28%
Fidelity Management & Research Company LLC
2.07%
T. Rowe Price Investment Management, Inc.
2.01%
其他
33.60%
持股股東
持股股東
佔比
AT Impf GmbH
42.36%
Medine GmbH
16.69%
Baillie Gifford & Co.
3.28%
Fidelity Management & Research Company LLC
2.07%
T. Rowe Price Investment Management, Inc.
2.01%
其他
33.60%
股東類型
持股股東
佔比
Corporation
59.74%
Investment Advisor
15.59%
Investment Advisor/Hedge Fund
3.82%
Individual Investor
2.11%
Research Firm
1.19%
Hedge Fund
1.05%
Sovereign Wealth Fund
0.63%
Bank and Trust
0.22%
Pension Fund
0.18%
其他
15.49%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
793
55.39M
23.04%
-2.63M
2025Q2
815
205.26M
85.38%
-4.32M
2025Q1
851
205.71M
85.57%
-4.55M
2024Q4
869
205.33M
85.56%
+3.19M
2024Q3
843
197.46M
82.52%
-2.61M
2024Q2
819
194.42M
81.78%
-7.50M
2024Q1
835
193.57M
81.42%
-10.02M
2023Q4
897
193.24M
81.29%
-7.90M
2023Q3
920
192.71M
79.62%
-7.47M
2023Q2
940
195.49M
80.61%
-8.54M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
AT Impf GmbH
101.85M
42.37%
-636.54K
-0.62%
Dec 31, 2024
Medine GmbH
40.13M
16.69%
-304.48K
-0.75%
Mar 31, 2025
Baillie Gifford & Co.
8.04M
3.34%
-120.81K
-1.48%
Jun 30, 2025
Fidelity Management & Research Company LLC
6.98M
2.9%
+1.02M
+17.22%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
3.60M
1.5%
+3.51M
+4076.79%
Jun 30, 2025
Flossbach von Storch AG
4.23M
1.76%
-29.53K
-0.69%
Jun 30, 2025
PRIMECAP Management Company
4.00M
1.66%
-44.96K
-1.11%
Jun 30, 2025
Dodge & Cox
877.44K
0.36%
+877.44K
--
Jun 30, 2025
Sahin (Ugur MD)
2.05M
0.85%
-724.50K
-26.11%
Mar 31, 2025
Pfizer Inc
3.66M
1.52%
--
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Langar Global HealthTech ETF
3.74%
iShares Genomics Immunology and Healthcare ETF
3.63%
Global X Genomics & Biotechnology ETF
3.06%
First Trust NYSE Arca Biotechnology Index Fund
2.71%
VanEck Biotech ETF
2.39%
Franklin Genomic Advancements ETF
2.28%
Virtus LifeSci Biotech Products ETF
1.57%
WisdomTree BioRevolution Fund
1.43%
ProShares Ultra Nasdaq Biotechnology
1.02%
Invesco Nasdaq Biotechnology ETF
1%
查看更多
Langar Global HealthTech ETF
佔比3.74%
iShares Genomics Immunology and Healthcare ETF
佔比3.63%
Global X Genomics & Biotechnology ETF
佔比3.06%
First Trust NYSE Arca Biotechnology Index Fund
佔比2.71%
VanEck Biotech ETF
佔比2.39%
Franklin Genomic Advancements ETF
佔比2.28%
Virtus LifeSci Biotech Products ETF
佔比1.57%
WisdomTree BioRevolution Fund
佔比1.43%
ProShares Ultra Nasdaq Biotechnology
佔比1.02%
Invesco Nasdaq Biotechnology ETF
佔比1%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Biontech SE的前五大股東是誰？
Biontech SE的前五大股東如下：
AT Impf GmbH持有股份：101.85M佔總股份比例：42.37%。
Medine GmbH持有股份：40.13M佔總股份比例：16.69%。
Baillie Gifford & Co.持有股份：8.04M佔總股份比例：3.34%。
Fidelity Management & Research Company LLC持有股份：6.98M佔總股份比例：2.90%。
T. Rowe Price Investment Management, Inc.持有股份：3.60M佔總股份比例：1.50%。
AT Impf GmbH持有股份：101.85M佔總股份比例：42.37%。
Medine GmbH持有股份：40.13M佔總股份比例：16.69%。
Baillie Gifford & Co.持有股份：8.04M佔總股份比例：3.34%。
Fidelity Management & Research Company LLC持有股份：6.98M佔總股份比例：2.90%。
T. Rowe Price Investment Management, Inc.持有股份：3.60M佔總股份比例：1.50%。
Biontech SE的前三大股東類型是什麼？
Biontech SE 的前三大股東類型分別是：
AT Impf GmbH
Medine GmbH
Baillie Gifford & Co.
AT Impf GmbH
Medine GmbH
Baillie Gifford & Co.
有多少機構持有Biontech SE(BNTX)的股份？
截至2025Q3，共有793家機構持有Biontech SE的股份，合計持有的股份價值約為55.39M，占公司總股份的23.04% 。與2025Q2相比，機構持股有所增加，增幅為-62.34%。
哪個業務部門對Biontech SE的收入貢獻最大？
在FY2019，Collaboration Revenue業務部門對Biontech SE的收入貢獻最大，創收84.43M，占總收入的77.75% 。
